|Bid||108.56 x 800|
|Ask||108.59 x 900|
|Day's Range||107.05 - 108.61|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||29.28|
|Earnings Date||Oct. 28, 2021 - Nov. 01, 2021|
|Forward Dividend & Yield||5.20 (4.86%)|
|Ex-Dividend Date||Oct. 14, 2021|
|1y Target Est||127.01|
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment.
This trio, with yields ranging from 4.7% to 5.4%, should net Berkshire Hathaway over $635 million in annual dividend income.
AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.